Strand SmartLab - Enabling Precision Medicine at community HospitalsHarsha Rajasimha
Strand SmartLab is a complete soup to nuts solution that enables a community hospital to establish precision medicine testing services in-house. This enables the retention of revenues internally rather than loosing them to external third party laboratories. Genomics driven precision medicine for Cancer and other diseases require highly skilled people, lab equipment, processes, regulatory experts, bigdata software, databases and curation, medical geneticists to interpret the results in clinical settings and genetic counselors. Strand SmartLab brings all these to your institution in a pre-packaged solution.
How to implement digital medicine in the futureYoon Sup Choi
by Yoon Sup Choi, PhD
yoonsup.choi@gmail.com
Professor, SAHIST, Sungkyunkwan University
Director, Digital Healthcare Institute
Managing Partner, Digital Healthcare Partners
With the help of Eggplant, UNC Health Care has been able to see a fast ROI. Eggplant has also allowed UNC Health Care to significantly reduce both the time and resources necessary for their integrated EPIC testing
Birmingham Heartlands Hospital in the U.K. has been using the Roche Digital Pathology portfolio to transform tissue diagnostics. They have streamlined collaboration, especially for their multi-disciplinary meetings and they have used digital technology in the education of new pathologists. Lab workflow has become more efficient and pathologists are now more seamlessly connected.
RTDPC-DP-0034b 6021A-3
DayOne Experts - Next generation clinical trialsDayOne
Event introduction slides by Thomas Brenzikofer.
Read the event report here:https://www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2019/06/on-the-verge-of-being-born-next-generation-clinical-trials.html
Tomasz Sablinski, Founder and CEO of Transparency Life Sciences raised the crunch question of the evening: Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”.
The idea of the event was to present a holistic view of the current standing in the digitizing clinical trials.
Touring the Universe (An Introduction to Formation of the Universe)
I hope this lesson can shed light to SHS Grade 11 Science Teachers. My appeal to those who will download this ppt. please email me at marileahmendina08@gmail.com for my own references. I would be glad to hear from you.
Strand SmartLab - Enabling Precision Medicine at community HospitalsHarsha Rajasimha
Strand SmartLab is a complete soup to nuts solution that enables a community hospital to establish precision medicine testing services in-house. This enables the retention of revenues internally rather than loosing them to external third party laboratories. Genomics driven precision medicine for Cancer and other diseases require highly skilled people, lab equipment, processes, regulatory experts, bigdata software, databases and curation, medical geneticists to interpret the results in clinical settings and genetic counselors. Strand SmartLab brings all these to your institution in a pre-packaged solution.
How to implement digital medicine in the futureYoon Sup Choi
by Yoon Sup Choi, PhD
yoonsup.choi@gmail.com
Professor, SAHIST, Sungkyunkwan University
Director, Digital Healthcare Institute
Managing Partner, Digital Healthcare Partners
With the help of Eggplant, UNC Health Care has been able to see a fast ROI. Eggplant has also allowed UNC Health Care to significantly reduce both the time and resources necessary for their integrated EPIC testing
Birmingham Heartlands Hospital in the U.K. has been using the Roche Digital Pathology portfolio to transform tissue diagnostics. They have streamlined collaboration, especially for their multi-disciplinary meetings and they have used digital technology in the education of new pathologists. Lab workflow has become more efficient and pathologists are now more seamlessly connected.
RTDPC-DP-0034b 6021A-3
DayOne Experts - Next generation clinical trialsDayOne
Event introduction slides by Thomas Brenzikofer.
Read the event report here:https://www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2019/06/on-the-verge-of-being-born-next-generation-clinical-trials.html
Tomasz Sablinski, Founder and CEO of Transparency Life Sciences raised the crunch question of the evening: Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”.
The idea of the event was to present a holistic view of the current standing in the digitizing clinical trials.
Touring the Universe (An Introduction to Formation of the Universe)
I hope this lesson can shed light to SHS Grade 11 Science Teachers. My appeal to those who will download this ppt. please email me at marileahmendina08@gmail.com for my own references. I would be glad to hear from you.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Connected Health is the way forward!
By improving this we can improve the Health of all. Advances in new technologies are being developed and implemented everyday. The key factor that connects and delivers all of these advances are health professionals.
Stredia are at the forefront of these innovative changes: Driving clinical improvement by engaging and supporting staff.
Bio dinner presentation 2016 plus about one nucleusTony Jones
With One Nucleus Corporate Sponsor Amgen acting as host, 5th June saw the largest and most diverse One Nucleus BIO Executive Dinner yet. The presentation sets out the what, why and who along with background information on One Nucleus and the London-Cambridge Life Science Cluster
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
Presentation from the Livestock Inter-Agency Donor Group (IADG) Meeting 2010. 4-5 May 2010 Italy, Rome IFAD Headquarters.
The event involved approximately 45 representatives from the international partner agencies to discuss critical needs for livestock development and research issues for the coming decade.
[ Originally posted on http://www.cop-ppld.net/cop_knowledge_base ]
Royal Veterinary College Business and International Engagement PresentationHorseTechConference
Slides to accompany the keynote talk by Tas Gohir, Head of Knowledge Transfer and Impact, Royal Veterinary College.
This presentation was delivered as the final keynote at the inaugural HorseTech Conference on the 18th October 2017 hosted by the Royal Veterinary College London.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
The Australian node of the Human Variome Project (HVPA) has established systems and processes for capturing, curating, interpreting and sharing genetic variant information for diagnostic, treatment and research purposes. To support the accurate interpretation of variant information, linkage to clinical treatment and outcomes data from relevant health service providers is required. Unfortunately, the required clinical data is not collected systematically within the Australian healthcare system and linkage of such data is beyond the scope and resources currently available to HVPA.
HVPA has partnered with BioGrid Australia, an independent not-for-profit organisation that provides a framework and infrastructure for data linkage and sharing that addresses patient privacy, data security, ethical issues and intellectual property concerns. Importantly, BioGrid’s vision and mission closely align with that of the Human Variome Project. Furthermore, BioGrid has existing relationships with, and linkages to clinical data from, numerous healthcare service providers, research institutes and universities around Australia.
While BioGrid’s governance and legal framework, coupled with its existing infrastructure, provides the requisite platform to achieving national linkage of clinical data with the HVPA collected variant data, this requires time and significant stakeholder engagement to achieve. However, within the existing network of HVPA and BioGrid collaborators, we are currently undertaking a project to demonstrate the real potential value of data linkages for clinical and research purposes.
A number of clinicians treating colorectal cancer at The Royal Melbourne Hospital are existing collaborators of both HVPA and BioGrid, providing an excellent opportunity to examine the potential benefits of data linkage. The pilot project is seeking to link deidentified, patient record level data from a range of sources with the goal of determining the depth and breadth of clinical data available for patients with specified variants at The Royal Melbourne Hospital. The secondary goal of this project is to determine whether, on review by subject matter experts, this clinical information can be used to support the determination of the pathogenicity of identified variants. We will discuss progress towards the first goal, however a detailed discussion of the second goal is beyond the scope of this abstract.
By using existing clinical datasets and BioGrid’s data linkage platform to integrate de-identified, patient record level clinical and genetic data, HVPA can efficiently build a national capability to capture, curate and interpret genetic variant information. Further leveraging BioGrid’s online data access application system that incorporates scientific review with ethics committee oversight, HVPA can also ensure that data is shared with authorised users for approved diagnostic, treatment and research purposes.
zkStudyClub - Reef: Fast Succinct Non-Interactive Zero-Knowledge Regex ProofsAlex Pruden
This paper presents Reef, a system for generating publicly verifiable succinct non-interactive zero-knowledge proofs that a committed document matches or does not match a regular expression. We describe applications such as proving the strength of passwords, the provenance of email despite redactions, the validity of oblivious DNS queries, and the existence of mutations in DNA. Reef supports the Perl Compatible Regular Expression syntax, including wildcards, alternation, ranges, capture groups, Kleene star, negations, and lookarounds. Reef introduces a new type of automata, Skipping Alternating Finite Automata (SAFA), that skips irrelevant parts of a document when producing proofs without undermining soundness, and instantiates SAFA with a lookup argument. Our experimental evaluation confirms that Reef can generate proofs for documents with 32M characters; the proofs are small and cheap to verify (under a second).
Paper: https://eprint.iacr.org/2023/1886
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
More Related Content
Similar to VPAC Health & Life Science Discussion at the Victorian Cancer BioBank
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Connected Health is the way forward!
By improving this we can improve the Health of all. Advances in new technologies are being developed and implemented everyday. The key factor that connects and delivers all of these advances are health professionals.
Stredia are at the forefront of these innovative changes: Driving clinical improvement by engaging and supporting staff.
Bio dinner presentation 2016 plus about one nucleusTony Jones
With One Nucleus Corporate Sponsor Amgen acting as host, 5th June saw the largest and most diverse One Nucleus BIO Executive Dinner yet. The presentation sets out the what, why and who along with background information on One Nucleus and the London-Cambridge Life Science Cluster
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
Presentation from the Livestock Inter-Agency Donor Group (IADG) Meeting 2010. 4-5 May 2010 Italy, Rome IFAD Headquarters.
The event involved approximately 45 representatives from the international partner agencies to discuss critical needs for livestock development and research issues for the coming decade.
[ Originally posted on http://www.cop-ppld.net/cop_knowledge_base ]
Royal Veterinary College Business and International Engagement PresentationHorseTechConference
Slides to accompany the keynote talk by Tas Gohir, Head of Knowledge Transfer and Impact, Royal Veterinary College.
This presentation was delivered as the final keynote at the inaugural HorseTech Conference on the 18th October 2017 hosted by the Royal Veterinary College London.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
The Australian node of the Human Variome Project (HVPA) has established systems and processes for capturing, curating, interpreting and sharing genetic variant information for diagnostic, treatment and research purposes. To support the accurate interpretation of variant information, linkage to clinical treatment and outcomes data from relevant health service providers is required. Unfortunately, the required clinical data is not collected systematically within the Australian healthcare system and linkage of such data is beyond the scope and resources currently available to HVPA.
HVPA has partnered with BioGrid Australia, an independent not-for-profit organisation that provides a framework and infrastructure for data linkage and sharing that addresses patient privacy, data security, ethical issues and intellectual property concerns. Importantly, BioGrid’s vision and mission closely align with that of the Human Variome Project. Furthermore, BioGrid has existing relationships with, and linkages to clinical data from, numerous healthcare service providers, research institutes and universities around Australia.
While BioGrid’s governance and legal framework, coupled with its existing infrastructure, provides the requisite platform to achieving national linkage of clinical data with the HVPA collected variant data, this requires time and significant stakeholder engagement to achieve. However, within the existing network of HVPA and BioGrid collaborators, we are currently undertaking a project to demonstrate the real potential value of data linkages for clinical and research purposes.
A number of clinicians treating colorectal cancer at The Royal Melbourne Hospital are existing collaborators of both HVPA and BioGrid, providing an excellent opportunity to examine the potential benefits of data linkage. The pilot project is seeking to link deidentified, patient record level data from a range of sources with the goal of determining the depth and breadth of clinical data available for patients with specified variants at The Royal Melbourne Hospital. The secondary goal of this project is to determine whether, on review by subject matter experts, this clinical information can be used to support the determination of the pathogenicity of identified variants. We will discuss progress towards the first goal, however a detailed discussion of the second goal is beyond the scope of this abstract.
By using existing clinical datasets and BioGrid’s data linkage platform to integrate de-identified, patient record level clinical and genetic data, HVPA can efficiently build a national capability to capture, curate and interpret genetic variant information. Further leveraging BioGrid’s online data access application system that incorporates scientific review with ethics committee oversight, HVPA can also ensure that data is shared with authorised users for approved diagnostic, treatment and research purposes.
zkStudyClub - Reef: Fast Succinct Non-Interactive Zero-Knowledge Regex ProofsAlex Pruden
This paper presents Reef, a system for generating publicly verifiable succinct non-interactive zero-knowledge proofs that a committed document matches or does not match a regular expression. We describe applications such as proving the strength of passwords, the provenance of email despite redactions, the validity of oblivious DNS queries, and the existence of mutations in DNA. Reef supports the Perl Compatible Regular Expression syntax, including wildcards, alternation, ranges, capture groups, Kleene star, negations, and lookarounds. Reef introduces a new type of automata, Skipping Alternating Finite Automata (SAFA), that skips irrelevant parts of a document when producing proofs without undermining soundness, and instantiates SAFA with a lookup argument. Our experimental evaluation confirms that Reef can generate proofs for documents with 32M characters; the proofs are small and cheap to verify (under a second).
Paper: https://eprint.iacr.org/2023/1886
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
UiPath Test Automation using UiPath Test Suite series, part 5DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 5. In this session, we will cover CI/CD with devops.
Topics covered:
CI/CD with in UiPath
End-to-end overview of CI/CD pipeline with Azure devops
Speaker:
Lyndsey Byblow, Test Suite Sales Engineer @ UiPath, Inc.
In his public lecture, Christian Timmerer provides insights into the fascinating history of video streaming, starting from its humble beginnings before YouTube to the groundbreaking technologies that now dominate platforms like Netflix and ORF ON. Timmerer also presents provocative contributions of his own that have significantly influenced the industry. He concludes by looking at future challenges and invites the audience to join in a discussion.
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
How to Get CNIC Information System with Paksim Ga.pptxdanishmna97
Pakdata Cf is a groundbreaking system designed to streamline and facilitate access to CNIC information. This innovative platform leverages advanced technology to provide users with efficient and secure access to their CNIC details.
UiPath Test Automation using UiPath Test Suite series, part 6DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 6. In this session, we will cover Test Automation with generative AI and Open AI.
UiPath Test Automation with generative AI and Open AI webinar offers an in-depth exploration of leveraging cutting-edge technologies for test automation within the UiPath platform. Attendees will delve into the integration of generative AI, a test automation solution, with Open AI advanced natural language processing capabilities.
Throughout the session, participants will discover how this synergy empowers testers to automate repetitive tasks, enhance testing accuracy, and expedite the software testing life cycle. Topics covered include the seamless integration process, practical use cases, and the benefits of harnessing AI-driven automation for UiPath testing initiatives. By attending this webinar, testers, and automation professionals can gain valuable insights into harnessing the power of AI to optimize their test automation workflows within the UiPath ecosystem, ultimately driving efficiency and quality in software development processes.
What will you get from this session?
1. Insights into integrating generative AI.
2. Understanding how this integration enhances test automation within the UiPath platform
3. Practical demonstrations
4. Exploration of real-world use cases illustrating the benefits of AI-driven test automation for UiPath
Topics covered:
What is generative AI
Test Automation with generative AI and Open AI.
UiPath integration with generative AI
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Unlocking Productivity: Leveraging the Potential of Copilot in Microsoft 365, a presentation by Christoforos Vlachos, Senior Solutions Manager – Modern Workplace, Uni Systems
Essentials of Automations: The Art of Triggers and Actions in FMESafe Software
In this second installment of our Essentials of Automations webinar series, we’ll explore the landscape of triggers and actions, guiding you through the nuances of authoring and adapting workspaces for seamless automations. Gain an understanding of the full spectrum of triggers and actions available in FME, empowering you to enhance your workspaces for efficient automation.
We’ll kick things off by showcasing the most commonly used event-based triggers, introducing you to various automation workflows like manual triggers, schedules, directory watchers, and more. Plus, see how these elements play out in real scenarios.
Whether you’re tweaking your current setup or building from the ground up, this session will arm you with the tools and insights needed to transform your FME usage into a powerhouse of productivity. Join us to discover effective strategies that simplify complex processes, enhancing your productivity and transforming your data management practices with FME. Let’s turn complexity into clarity and make your workspaces work wonders!
In the rapidly evolving landscape of technologies, XML continues to play a vital role in structuring, storing, and transporting data across diverse systems. The recent advancements in artificial intelligence (AI) present new methodologies for enhancing XML development workflows, introducing efficiency, automation, and intelligent capabilities. This presentation will outline the scope and perspective of utilizing AI in XML development. The potential benefits and the possible pitfalls will be highlighted, providing a balanced view of the subject.
We will explore the capabilities of AI in understanding XML markup languages and autonomously creating structured XML content. Additionally, we will examine the capacity of AI to enrich plain text with appropriate XML markup. Practical examples and methodological guidelines will be provided to elucidate how AI can be effectively prompted to interpret and generate accurate XML markup.
Further emphasis will be placed on the role of AI in developing XSLT, or schemas such as XSD and Schematron. We will address the techniques and strategies adopted to create prompts for generating code, explaining code, or refactoring the code, and the results achieved.
The discussion will extend to how AI can be used to transform XML content. In particular, the focus will be on the use of AI XPath extension functions in XSLT, Schematron, Schematron Quick Fixes, or for XML content refactoring.
The presentation aims to deliver a comprehensive overview of AI usage in XML development, providing attendees with the necessary knowledge to make informed decisions. Whether you’re at the early stages of adopting AI or considering integrating it in advanced XML development, this presentation will cover all levels of expertise.
By highlighting the potential advantages and challenges of integrating AI with XML development tools and languages, the presentation seeks to inspire thoughtful conversation around the future of XML development. We’ll not only delve into the technical aspects of AI-powered XML development but also discuss practical implications and possible future directions.
Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!SOFTTECHHUB
As the digital landscape continually evolves, operating systems play a critical role in shaping user experiences and productivity. The launch of Nitrux Linux 3.5.0 marks a significant milestone, offering a robust alternative to traditional systems such as Windows 11. This article delves into the essence of Nitrux Linux 3.5.0, exploring its unique features, advantages, and how it stands as a compelling choice for both casual users and tech enthusiasts.
GridMate - End to end testing is a critical piece to ensure quality and avoid...ThomasParaiso2
End to end testing is a critical piece to ensure quality and avoid regressions. In this session, we share our journey building an E2E testing pipeline for GridMate components (LWC and Aura) using Cypress, JSForce, FakerJS…
GridMate - End to end testing is a critical piece to ensure quality and avoid...
VPAC Health & Life Science Discussion at the Victorian Cancer BioBank
1. Health & Life Science
A tailored solution, to meet your needs
2. Introduction
Victorian Partnership For Advanced Computing LTD
• A Not for Profit “R&D Services” company
• Founded in 2000 by a consortium of universities
Life
GIS
Science
• Expanding Membership
Adv
VE Health
Comp
• Employ over 60 staff in specialist fields
• “Our aim is to help Australians utilise research tools and advanced
computing to create innovations that will place Australia at the
forefront of global scientific achievement.”
3. Health & Life Science Initiatives
For improved health outcomes
• Coupling Expert Scientists, Technologists & Infrastructure
• Health Services
– Systems Integration
– Clinical Application & Database Development
– Secure Health Data Hosting
• Life Science Services
– Modelling & Visualisation
– Computational Biology & Bioinformatics
– Virtual Screening & Ligand Analysis
– Full Life Cycle Systems Biology
4. Advanced Computing Initiatives
To improve your business
• Complete solutions to meet your business needs
• Advanced Computing
– Consultancy Services
– Systems Management
– Systems Engineering
– Large Scale Storage
– Visualisation Facilities
– High Performance Computing
5. Pairing Services, to Obtain Results
Using VPAC HPC facilities and expert Life Science staff, researchers at Monash University and the Peter MacCallum Cancer Centre in Melbourne
were able to establish that Perforin proteins “break into cells that have been hijacked by viruses or turned into cancer cells and allows toxic
enzymes in, to destroy the cell from within.”
6. Limitations Opportunities
Innovative, cost effective, results oriented
• Bridging the gaps
– Pairing experts
– Full Time professionals
• Providing solutions
– Prototyping
– Bleeding edge
7. Current Solutions
Infinite Innovation
– Software Development
• Diabetes Clinical Portal (BioGrid Aus – 5 hospitals)
• Obesity Clinical Portal (VPAC – 2 hospitals)
• HL7 Engine (Vetinari) (VPAC – 3 hospitals)
• Tuberculosis Portal (St Vincent’s Hosp – 2 hospitals)
• iMDT Cancer Services (MDM) Portal (St Vincent’s Hosp)
• Pituitary Clinical Platform (BioGrid Aus - 3 hospitals)
• BioSpecimen Viewer
– Secure Hosting
• Aperio Hosting (VicCancer BioBank)
• Cresalys Hosting (VicCancer BioBank)
• GRHANITE Secure Data Hosting (Uni Melbourne)
• PHA Data Hosting (CSIRO)
• Precedence Health Hosting (Precedence Health)
– Research & Development
• MISLE Omics Platform (Bio21)
• Mass Spectrometry Software (Mascot) (VPAC)
• The Human Variome Project (Aus) (Uni Melbourne)
• Bioinformatics Computing (Dell & AMD)
8. For more...
Infinite Innovation
Don’t forget, none of this could be possible without our partners
and the clinicians they support!
Key Partners Research Institutes
Victorian Cancer BioBank Australian Catholic University
BioGrid Australia Ludwig Institute for Cancer Research Ltd
Bio21 Institute St Vincent’s Institute
HVP Australia Tissupath Ltd
Dell & AMD University of Melbourne
Victorian Breast Cancer Research Consortium Victorian
Transplantation and Immunogenetics Service
Hospitals We Work With
Walter and Eliza Hall Institute of Medical Research
Austin Health
BakerIDI
Pharmaceutical Companies
Eastern Health Epworth Eastern Freemason's Hospital
Goulburn Valley Health Biota
Northern Health CSL Ltd
Peter MacCallum Cancer Centre GlaxoSmithKline
Royal Adelaide Hospital Novartis
Royal Melbourne Hospital/Melbourne Health Roche
Royal Children's Hospital/Murdoch Children's Research Institute
Southern Health St Vincent's (Public) Hospital & St Vincent’s
Private
The Royal Women's Hospital Western Health
9. Our Team
I couldn’t do it without my team!
• Alan Lo • Daniel Micevski
• Andrew Spiers • David Perkins
• Andrew Underwood (me) • Jin Park
• Melvin Luong
10. For more...
Infinite Innovation
• For a deeper look into the potential innovations;
– http://www.vpac.org
– http://www.linkedin.com/company/VPAC
– https://www.facebook.com/VPACltd
– http://twitter.com/VPACltd
Don’t forget, none of this could be possible without our key partners and
the clinicians they support!
– Victorian Cancer BioBank
– BioGrid Australia
– Bio21 Institute
– HVP Australia
– Ludwig Institute
– Dell & AMD